EVOQ Therapeutics Gains $2M for Autoimmune NanoDisc Therapies

EVOQ Therapeutics, Inc. has announced the receipt of a $2 million grant from the National Institutes of Health (NIH) to further its work on innovative treatments for autoimmune diseases. The biopharmaceutical company, which operates out of ANN ARBOR, Mich. and CHICAGO, specializes in developing therapies that utilize the immune system's capabilities to both treat and prevent autoimmune conditions.

This NIH grant is a significant endorsement of EVOQ's pioneering approach, specifically its NanoDisc technology. Dr. James Moon, Chief Scientific Officer of EVOQ Therapeutics, expressed excitement about the grant, emphasizing that it highlights the transformative potential of their NanoDisc platform in the field of immunotherapy. According to Dr. Moon, this financial support will be pivotal in accelerating the development of treatments for various autoimmune diseases, particularly myelin oligodendrocyte glycoprotein (MOG) antibody disease. MOG antibody disease is a rare and severe inflammatory condition affecting the central nervous system, including the optic nerves, brain, and spinal cord.

NanoDisc technology represents a novel approach by reducing the body's abnormal immune responses that cause autoimmunity. This targeted method reeducates the immune system through local administration, aiming to address unmet medical needs across a spectrum of autoimmune disorders. The technology has the potential to offer more precise treatment options, reducing the general immune suppression that is often associated with current therapies.

Dr. David Giljohann, CEO of EVOQ Therapeutics, reiterated the company's commitment to advancing immunotherapy. He noted that the NIH grant is a significant milestone in their mission to provide much-needed treatments to patients worldwide. Aside from focusing on MOG antibody disease, EVOQ is also developing therapies for a range of other autoimmune conditions, including Type 1 diabetes, Celiac disease, Rheumatoid arthritis, and Lupus.

MOG antibody disease is characterized by its impact on the central nervous system, leading to symptoms such as vision loss, spinal cord damage, and seizures. The current treatment options involve steroids and immunosuppressants, which often result in systemic immunosuppression, complications, and frequent relapses. This situation underscores the urgent need for more targeted and effective therapies, which EVOQ aims to deliver through its NanoDisc technology.

EVOQ Therapeutics is actively working on a pipeline of disease-specific immune modulators intended for patients suffering from various autoimmune diseases. Their proprietary NanoDisc platform has been engineered to deliver antigens effectively, thereby restoring immune tolerance. The company was established with support from Innovation Partnerships at the University of Michigan, which has helped them in their ambitious quest to innovate within the field of immunotherapy.

In summary, the $2 million NIH grant awarded to EVOQ Therapeutics serves as a crucial boost to their ongoing efforts in developing groundbreaking treatments for autoimmune diseases. Their NanoDisc technology presents a promising avenue for precisely targeting and modulating the immune system, potentially transforming the way autoimmune diseases are treated. With this support, EVOQ Therapeutics is well-positioned to make significant advancements in providing targeted, effective treatments for patients suffering from these challenging conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!